丙酸氟替卡松联合布地奈德治疗小儿支气管哮喘对细胞间黏附分子-1、血浆P物质浓度及唾液分泌型免疫球蛋白A的影响分析

目的探讨丙酸氟替卡松联合布地奈德治疗小儿支气管哮喘对细胞间黏附分子-1(ICAM-1)、血浆P物质(SP)浓度及唾液分泌型免疫球蛋白A(sIgA)的影响。方法选取2018年7月至2019年7月莱州市中医医院儿科收治的82例支气管哮喘患儿,男43例,女39例,年龄(6.52±2.36)岁,年龄范围为3~11岁,采用电脑数字表法将其随机分为单药治疗组与单药治疗组,每组41例。单药治疗组行布地奈德治疗,联合治疗组行丙酸氟替卡松联合布地奈德治疗,比较两组患儿ICAM-1、SP浓度、唾液sIgA、肺功能[用力肺活量(FVC)、1 s用力呼气容积(FEV1)]水平及不良反应发生情况。结果治疗后,联合治疗组患儿ICAM-1[(218.25±2.13)μg/L]、SP浓度[(41.44±2.21)μg/L]低于单药治疗组[(234.65±2.18)μg/L、(49.73±2.26)μg/L],唾液sIgA[(17.39±1.12)μg/L]高于单药治疗组[(13.56±1.23)μg/L],联合治疗组FVC[(3.53±0.25)L]、FEV1[(2.72±0.23)L]高于单药治疗组[(2.61±0.32)L、(2.24±0.35)L],差异有统计学意义(P<0.05);联合治疗组不良反应发生率[9.8%(4/41)]与单药治疗组[7.3%(3/41)]比较,差异无统计学意义(P>0.05)。结论丙酸氟替卡松联合布地奈德治疗小儿支气管哮喘可有效降低患儿ICAM-1、SP浓度、提升唾液sIgA水平,改善患儿肺功能,不增加药物不良反应。

Effects of fluticasone propionate combined with budesonide on intercellular adhesion molecule-1,plasma substance P concentration and salivation immunoglobulin A in children with bronchial asthma

Objective To investigate the effects of fluticasone propionate combined with budesonide on intercellular adhesion molecule-1(ICAM-1),plasma substance P(SP)concentration and salivary immunoglobulin A(sIgA)in children with bronchial asthma.Methods A retrospective study was performed 82 cases of child patients with bronchial asthma who were admitted from July 20 to July 2019.There were 43 males and 39 females,aged(6.52±2.36)years,ranging from 3 to 11 years.According to the computer digital table method randomly divided into two groups,41 cases in each group.The control group was treated with budesonide.The experimental group was treated with fluticasone propionate combined with budesonide.The efficacy and ICAM-1,SP concentration and salivary sIgA were compared between the two groups.Results After treatment,ICAM-1[(218.25±2.13)μg/L],SP concentration[(41.44±2.21)μg/L]in the combined treatment group was lower than that in the monotherapy group[(234.65±2.18)μg/L,(49.73±2.26)μg/L]and saliva sIgA[(17.39±1.12)μg/L],FVC[(3.53±0.25)L],FEV1[(2.72±0.23)L]in the combination treatment group was higher than that in the monotherapy group[(13.56±1.23)μg/L,(2.61±0.32)L,(2.24±0.35)L],and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the combination group[9.8%(4/41)]had not statistically significant difference from that in the monotherapy group[7.3%(3/41)],(P>0.05).Conclusion Fluticasone propionate combined with budesonide in the treatment of children with bronchial asthma can effectively reduce the concentration of ICAM-1 and SP,increase the level of saliva sIgA,improve the lung function of children without increasing adverse drug reactions.